Sirnaomics

Sirnaomics Advances STP705 for Squamous Cell Carcinoma In Situ into Late-Stage Clinical Development

by

HONG KONG, GERMANTOWN, Md. and SUZHOU, China, June 19, 2023 /PRNewswire/ — Sirnaomics Ltd. (the “Company”; stock code: 2257, together with its subsidiaries, the “Group” or “Sirnaomics”), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, today announced the advancement of STP705 for the treatment of Squamous Cell Carcinoma in situ (isSCC) into late-stage … Read more

Sirnaomics to Present Latest Developments on GalAhead™ Therapeutic Platform at Upcoming Industry Conferences

by

HONG KONG, GERMANTOWN, Md. and SUZHOU, China, June 13, 2023 /PRNewswire/ — Sirnaomics Ltd. (the “Company”; stock code: 2257, together with its subsidiaries, the “Group” or “Sirnaomics”), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, today announced that the Company will present the latest developments on GalAhead™, a GalNAc-RNAi therapeutic platform, and its pipeline programs, at three … Read more

Sirnaomics Reports Interim Results of STP705 Phase I Clinical Study for Medical Aesthetics Treatment in Adults Undergoing Abdominoplasty

by

HONG KONG, GERMANTOWN, Md. and SUZHOU, China , June 5, 2023 /PRNewswire/ — Sirnaomics Ltd. (the “Company”, Stock Code: 2257.HK, together with its subsidiaries, the “Group” or “Sirnaomics”), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, today announced the interim results of an ongoing Phase I clinical trial of STP705, an siRNA (small interfering RNA) … Read more